Prophy Treatment Research is Promising

Roche announced positive data from its Phase I/II NXTAGE trial of NXT007, a next-generation investigational therapy intended as a prophylactic treatment option for persons with hemophilia A. Their findings were presented at the International Society on Thrombosis and Haemostasis (ISTH) Congress in Washington, D.C. NXT007 is a bispecific antibody derived from Roche’s Hemlibra that similarly mimics the action of factor VIII by bridging activated factor IXa and factor X, but has been engineered by Roche group member CHUGAI to optimize factor VIII mimetic activity and half-life, with the goal of enhancing potency while reducing required dosing frequency.

Source: LA Kelley Communications, Inc., Communique, July 2025